The patient (case 1) was a 72 year old female with multiinfarct dementia. Four months before our examination she had been started on a regimen of calcium hopantenate therapy (37 mg/kg/&). One day before the examination, with no prodromal symptoms, she developed severe nausea and vomiting, and then became stuporous. On examination her vital signs were as follows: temperature 35 6°C; pulse, 96 beats/min, respiration, 36/min, and BP, 160/70mmHg. She was deeply comatose and unresponsive to noxious stimuli. Pupils were small and reactive to light. Her upper limbs were flaccid and her lower limbs were spastic in flexion, a condition present since the age of 70 years. Deep tendon reflexes were brisk in all four extremities. Hepatosplenomegaly was not observed.
dihydroxy-3,3-dimethyl-butyramido) butyrate, hemihydrate is obtained by substituting the ,B-alanine moiety of pantothenic acid for gamma aminobutyric acid (GABA) and has a GABAergic effect on the central nervous system.' It has been available only in Japan (since 1978) for treatment of diminished reactivity in organic brain diseases of children and adults. 2 Between 1983 and 1985, 11 Japanese children were reported to have developed a Reye- Calcium hopantenate has a structural formula similar to that of pantothenic acid and is a pantothenic acid antagonist.7 The activity is three times more potent than that of omega-methyl pantothenic acid, which is a well-studied pantothenic acid antagonist.7 1 High serum levels of calcium hopantenate and low levels of pantothenic acid in case 1 suggest that the drug may reduce the concentration of pantothenic acid by an unknown mechanism. In addition, calcium hopantenate may inhibit utilisation of pantothenic acid in the tissue because it is concentrated mainly in the liver following oral administration."2 Liver is therefore presumed to be more affected by pantothenic acid deficiency than are other organs.'3 The fatty livers in the chicks and dogs produced by calcium hopantenate were prevented by addition of pantothenic acid. 7 9 On the basis of these data,.we suggest the possibility that the pathogenesis of the Reye-like syndrome may be due to pantothenic acid deficiency produced by calcium hopantenate.
Pantothenic acid is a constituent of coenzyme A (CoA) and the level of CoA is greatest in liver mitochondria."' CoA serves as a cofactor to yield important compounds in the tricarboxylic cycle, such as acetyl-CoA and succinyl-CoA. In theory, pantothenic acid deficiency appears to deplete those compounds and to inhibit the tricarboxylic cycle, which may produce the Reye-like syndrome. A similar deficiency mechanism may be involved in fatty-liver-and-kidney syndrome of fowls,15 which resembles Reye's syndrome and is believed to result from a deficiency of biotin.
In animals, the classic symptoms of pantothenic acid deficiency vary according to the species.'6 The work of Schaefer et al'7 is of interest. These authors described pantothenic acid deficiency in dogs as being characterised by sudden prostration or coma, vomiting, convulsions, hypoglycaemia and fatty livers, all signs that resemble Reye's syndrome. After administration of a diet low in pantothenic acid, together with a pantothenic acid antagonist, omega-methyl pantothenic acid, no Reye-like syndrome was reported in Reye-like syndrome following treatment with the pantothenic acid antagonist, calcium hopantenate human investigations.'8 19 However, these results do not rule out our hypothesis, because omega-methyl pantothenic acid is less potent than calcium hopantenate, and the cited studies are limited in the dose used and the duration of the administration.
The hepatoxicity of calcium hopantenate may be another possible explanation for the disorder. However the LD50 of the agent is 5-72g/kg and that of pantothenic acid is 2-49 g/kg.' 9 Pantothenic acid is believed to be nontoxic; as much as 10 g can be given daily to men for 6 weeks without producing symptoms.20 Therefore, a toxic aetiology seems unlikely.
